메뉴 건너뛰기




Volumn 73, Issue 3, 2012, Pages 391-401

Mechanism-based population pharmacokinetic modelling in diabetes: Vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV

Author keywords

DPP 4 inhibitor; Mechanism based population modelling; Pharmacokinetics; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DRUG METABOLITE; PLACEBO; VILDAGLIPTIN;

EID: 84863018661     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04108.x     Document Type: Article
Times cited : (30)

References (22)
  • 1
    • 34248590514 scopus 로고    scopus 로고
    • The role of vildagliptin in the management of type 2 diabetes mellitus
    • Kleppinger EL, Helms K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother 2007; 41: 824-32.
    • (2007) Ann Pharmacother , vol.41 , pp. 824-832
    • Kleppinger, E.L.1    Helms, K.2
  • 2
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
    • (2007) Gastroenterology , vol.132 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 3
    • 33846844912 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug
    • Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 2007; 9: 153-65.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 153-165
    • Idris, I.1    Donnelly, R.2
  • 5
    • 84875670059 scopus 로고    scopus 로고
    • Non-compartmental analysis
    • In:, eds. D'Agostino RB, Sullivan L, Massaro J. Hoboken: Wiley & Sons, dx.doi.org/10.1002/9780471462422.eoct340
    • Bulitta JB, Holford NHG. Non-compartmental analysis. In: Wiley Encyclopedia of Clinical Trials, eds. D'Agostino RB, Sullivan L, Massaro J. Hoboken: Wiley & Sons, 2008; dx.doi.org/10.1002/9780471462422.eoct340
    • (2008) Wiley Encyclopedia of Clinical Trials
    • Bulitta, J.B.1    Holford, N.H.G.2
  • 6
    • 34548324787 scopus 로고    scopus 로고
    • The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
    • He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 787-802
    • He, Y.L.1    Sadler, B.M.2    Sabo, R.3    Balez, S.4    Wang, Y.5    Campestrini, J.6    Laurent, A.7    Ligueros-Saylan, M.8    Howard, D.9
  • 8
    • 84863014645 scopus 로고    scopus 로고
    • S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA.
    • Bauer RJ. S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA. 2008.
    • (2008)
    • Bauer, R.J.1
  • 9
    • 84863021457 scopus 로고    scopus 로고
    • Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes
    • Landersdorfer CB, He Y-L, Jusko WL. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol 2012; 73: 373-390.
    • (2012) Br J Clin Pharmacol , vol.73 , pp. 373-390
    • Landersdorfer, C.B.1    He, Y.-L.2    Jusko, W.L.3
  • 10
    • 0027998106 scopus 로고
    • Pharmacologic target-mediated drug disposition
    • Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248-52.
    • (1994) Clin Pharmacol Ther , vol.56 , pp. 248-252
    • Levy, G.1
  • 11
    • 0035730322 scopus 로고    scopus 로고
    • General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
    • Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-32.
    • (2001) J Pharmacokinet Pharmacodyn , vol.28 , pp. 507-532
    • Mager, D.E.1    Jusko, W.J.2
  • 13
    • 33646901012 scopus 로고    scopus 로고
    • Target-mediated drug disposition and dynamics
    • Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72: 1-10.
    • (2006) Biochem Pharmacol , vol.72 , pp. 1-10
    • Mager, D.E.1
  • 14
    • 20444406121 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile
    • Brandt I, Joossens J, Chen X, Maes MB, Scharpe S, De Meester I, Lambeir AM. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile. Biochem Pharmacol 2005; 70: 134-43.
    • (2005) Biochem Pharmacol , vol.70 , pp. 134-143
    • Brandt, I.1    Joossens, J.2    Chen, X.3    Maes, M.B.4    Scharpe, S.5    De Meester, I.6    Lambeir, A.M.7
  • 15
    • 0033533402 scopus 로고    scopus 로고
    • NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV
    • Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999; 38: 11597-603.
    • (1999) Biochemistry , vol.38 , pp. 11597-11603
    • Hughes, T.E.1    Mone, M.D.2    Russell, M.E.3    Weldon, S.C.4    Villhauer, E.B.5
  • 16
    • 0033619675 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
    • Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
    • (1999) Regul Pept , vol.85 , pp. 9-24
    • Mentlein, R.1
  • 18
    • 0037777695 scopus 로고    scopus 로고
    • 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
    • Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-89.
    • (2003) J Med Chem , vol.46 , pp. 2774-2789
    • Villhauer, E.B.1    Brinkman, J.A.2    Naderi, G.B.3    Burkey, B.F.4    Dunning, B.E.5    Prasad, K.6    Mangold, B.L.7    Russell, M.E.8    Hughes, T.E.9
  • 19
    • 77955809148 scopus 로고    scopus 로고
    • Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients
    • Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010; 50: 873-85.
    • (2010) J Clin Pharmacol , vol.50 , pp. 873-885
    • Retlich, S.1    Duval, V.2    Graefe-Mody, U.3    Jaehde, U.4    Staab, A.5
  • 20
    • 33947234683 scopus 로고    scopus 로고
    • Nonlinearity detection: advantages of nonlinear mixed-effects modeling
    • Jonsson EN, Wade JR, Karlsson MO. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2000; 2: E32.
    • (2000) AAPS PharmSci , vol.2
    • Jonsson, E.N.1    Wade, J.R.2    Karlsson, M.O.3
  • 21
    • 0035216180 scopus 로고    scopus 로고
    • Ways to fit a PK model with some data below the quantification limit
    • Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
    • (2001) J Pharmacokinet Pharmacodyn , vol.28 , pp. 481-504
    • Beal, S.L.1
  • 22
    • 34247887681 scopus 로고    scopus 로고
    • A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
    • Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
    • (2007) AAPS J , vol.9
    • Bauer, R.J.1    Guzy, S.2    Ng, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.